Lion adds new cancer indications to NIH license

Lion Biotechnologies Inc. (NASDAQ:LBIO) gained $0.80 (14%) to $6.43 on Wednesday after it received an exclusive, worldwide license to use NIH's tumor-infiltrating lymphocytes (TIL) in four new oncology indications, amending an existing agreement.

The amendment gives Lion rights to develop TIL therapies to treat bladder, lung, breast and HPV-associated cancers. In February, Lion acquired an exclusive license from NIH to develop TIL immunotherapies to treat metastatic melanoma. ...